Skip to main content
Shifting the Management Paradigm for SLE and Lupus Nephritis
The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes.

If vagus nerve stimulation improves RA; then what if vagotomy? Danish study of vagotomy (1977-1995). 6070 vagotomy match

Social Author Name
Dr. John Cush
Tweet Content
If vagus nerve stimulation improves RA; then what if vagotomy? Danish study of vagotomy (1977-1995). 6070 vagotomy matched w/ 60,699 comparators. Truncal vagotomy was assoc w/ signif incr RA incidence (OR 2.62), but not superselective vagotomy (OR 1.05). NO diff in incident OA https://t.co/Rs1EyrQd57

Neutrophil alkaline phosphatase (NAP) elevated in active AOSD. 141 AOSD compared to Bcell lymphoma, SLE, aPL & contr

Social Author Name
Dr. John Cush
Tweet Content
Neutrophil alkaline phosphatase (NAP) elevated in active AOSD. 141 AOSD compared to Bcell lymphoma, SLE, aPL & controls. NAP pos. correl w/ Systemic Dz activity score (R=0.71), & 0.59 for CRP/ANC/ferritin. NAP scores higher in pre-MAS, but lower w/ MAS (w/lower WBC). NAP responds https://t.co/YbYPaJUEbz

Infusion/injxn-reactions (IRRs) w/ biologics studied in 1,832 RA pts - IRRs seen in 9.7% & were signif more common

Social Author Name
Dr. John Cush
Tweet Content
Infusion/injxn-reactions (IRRs) w/ biologics studied in 1,832 RA pts - IRRs seen in 9.7% & were signif more common w/ being younger (OR1.79), secondary Sjögren's (OR 2.17), prior leflunomide (OR 1.5); but less common w/ Abatacept (OR 0.26) & tocilizumab (OR 0.42), golimumab (OR https://t.co/IaHajITWri

Emerging therapies targeting the NLRP3-inflammasome (active in Autoinflammatory Dz, Gout, neurodegenerative Dz/Alzheimer

Social Author Name
Dr. John Cush
Tweet Content
Emerging therapies targeting the NLRP3-inflammasome (active in Autoinflammatory Dz, Gout, neurodegenerative Dz/Alzheimers). Currently no FDA approved drugs, but many in trials. eg, Oxidized DNA (DAMP) activates NLRP3 & may be blocked by repurposed glycosylase inhibitors to reduce https://t.co/CJv50LVKhy

CAR-T and cellular depletion therapies gone wild! Currently there are over 85 different therapeutic candidates aiming to

Social Author Name
Dr. John Cush
Tweet Content
CAR-T and cellular depletion therapies gone wild! Currently there are over 85 different therapeutic candidates aiming to reset the immune system in >380 clinical trials. Review article looks at indications, targets, modalities & outlook. https://t.co/yleR4B48IY https://t.co/WwSPzIPomk

QD Clinic - Tackling Lupus Pregnancies Managing Lupus Pregnancy - pre-pregnancy, labs & safe drugs https://t.co/

Social Author Name
Dr. John Cush
Tweet Content
QD Clinic - Tackling Lupus Pregnancies Managing Lupus Pregnancy - pre-pregnancy, labs & safe drugs https://t.co/rtDVCCVqnD https://t.co/IRi1qYYqAA

Lupus Slides: Set 2

Join The Discussion

Panacea of Prednisone & Cannabis (5.16.2025) Dr. Jack Cush reviews the news, journal and regulatory reports from t

Social Author Name
Dr. John Cush
Tweet Content
Panacea of Prednisone & Cannabis (5.16.2025) Dr. Jack Cush reviews the news, journal and regulatory reports from this week on RheumNow. Interesting trends and results with prednisone in lupus, cannabis in RA and opioid deaths too! https://t.co/QDtxItYSco https://t.co/s4nYmMe3vs
Subscribe to
×